Comparative Pharmacology
Head-to-head clinical analysis: RALTEGRAVIR POTASSIUM versus VOCABRIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RALTEGRAVIR POTASSIUM versus VOCABRIA.
RALTEGRAVIR POTASSIUM vs VOCABRIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Raltegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration, which is essential for viral replication.
Cabotegravir is an HIV-1 integrase strand transfer inhibitor (INSTI) that inhibits viral replication by blocking the integration of HIV-1 DNA into host genomic DNA.
400 mg orally twice daily, with or without food. Administered as two 200 mg tablets or one 400 mg tablet.
600 mg intramuscularly once monthly, initiated with a single 600 mg dose and a second 600 mg dose 4 weeks later, then every 4 weeks thereafter.
None Documented
None Documented
Terminal elimination half-life is approximately 9 hours (range 7–12 hours); supports twice-daily dosing; t1/2 is prolonged in hepatic impairment (Child-Pugh B/C) but no dose adjustment recommended.
Terminal elimination half-life: 35 hours (range 31–41 hours). At steady state, drug accumulates ~1.4-fold; half-life supports monthly IM dosing.
Primarily hepatic metabolism via UGT1A1-mediated glucuronidation; <2% excreted unchanged in urine; approximately 51% of dose recovered in feces (as parent and metabolites) and 32% in urine (as metabolites); biliary/fecal elimination accounts for the majority.
Renal (unchanged): <1%; fecal: >90% as parent drug; biliary contribution minimal; predominantly eliminated via feces as unchanged drug.
Category A/B
Category C
Integrase Strand Transfer Inhibitor
Integrase Strand Transfer Inhibitor